Regor Therapeutics and NVIDIA Forge Strategic Partnership to Build Next-Gen AI-Powered Drug Discovery Engine

Recently, Regor Therapeutics Group (Regor Therapeutics) and NVIDIA Corporation have reached a strategic partnership. Regor Therapeutics has become a deep cooperation partner in China's innovative drug field under the NVIDIA Inception program. Regor Therapeutics will closely collaborate with NVIDIA to integrate high-performance computing technology into its self-developed rCARD™ platform, accelerating the initial discovery and development of innovative drugs.

NVIDIA Inception Program is an initiative aimed at nurturing cutting-edge startups. In this collaboration with Regor Therapeutics, NVIDIA will contribute its leading GPU products and technologies in the computing field to the rCARD™ platform, including suites from the NVIDIA Clara Discovery Pipeline such as GROMACS and Autodock-GPU, among others. Leveraging GPU-powered parallel processing capabilities, the program will accelerate the drug discovery process, reduce R&D costs, enhance the efficiency of drug development, and support Regor Therapeutics in developing more and better potential first-in-class and best-in-class innovative drugs.

Regor Therapeutics' rCARD™ platform is a self-developed, high-efficiency computer-accelerated drug discovery platform that utilizes cutting-edge artificial intelligence algorithms, integrating structural biology, bioinformatics, computational chemistry, and other disciplines, as well as various drug discovery approaches and years of industry experience, achieving a high level of integration between artificial intelligence and the biopharmaceutical industry. Regor Therapeutics will comprehensively upgrade the rCARD™ platform. This strategic collaboration leverages NVIDIA Corporation’s technical advantages in high-performance computing (HPC) to further establish it as a new generation world-class innovative drug discovery engine.

The integration of artificial intelligence technology with the biopharmaceutical industry is entering a new phase of development, bringing both opportunities and challenges. Traditional biopharmaceutical industries rely on high-throughput screening methods to identify target compounds, which involve high costs in terms of labor, time, and trial-and-error. In the era of big data, virtual computing platforms powered by artificial intelligence can build data models based on the correlation mechanisms between genes and diseases, efficiently identify new drug targets, design and synthesize bioactive molecules, and predict efficacy, pharmacokinetics, toxicity, stability, and more during the drug discovery and development process. This significantly reduces R&D costs, enhances the overall efficiency and success rate of innovative drug development, ultimately benefiting patients worldwide.

Dr. Zhong Wenge, Chief Technology Officer of Regor Therapeutics Group, said: "We highly value the application and potential disruptive impact of new technologies in the field of innovative drug research and development. Since its establishment, Regor Therapeutics has built a cross-disciplinary team of scientists and started to develop the rCARD™ platform, integrating industry experience with artificial intelligence. We are delighted to reach an in-depth collaboration with NVIDIA Corporation, a leading company in artificial intelligence and high-performance computing, to further upgrade our technology platform, accelerate the construction of a rich R&D pipeline, and jointly define the future of artificial intelligence in the field of innovative drug research and development."

"NVIDIA's Global Healthcare Startup Director Renee Yao said, 'We are thrilled to collaborate with Regor Therapeutics to jointly initiate a new chapter of integrating artificial intelligence into the biopharmaceutical industry. Through this partnership, we will systematically enhance Regor Therapeutics' HPC and AI capabilities on NVIDIA’s software-defined computing platform, accelerating the integration of multidisciplinary technologies such as big data, artificial intelligence, high-performance computing, and innovative drug development.'"

About Regor Therapeutics

Regor Therapeutics is a clinical-stage biopharmaceutical high-tech company. In the three and a half years since its establishment, by leveraging its AI-accelerated new drug discovery rCARD™ platform, the company has locked onto "long-unconquered" targets in the pharmaceutical field and developed innovative drugs with clinically differentiated advantages. The company focuses on three major therapeutic areas: oncology, immunology, and metabolism. Regor Therapeutics' rCARD™ platform deeply integrates cross-disciplinary knowledge and industry experience, including structural biology, computational chemistry, biology, medicinal chemistry, and clinical development. To date, Regor Therapeutics has successfully built a multidisciplinary, experienced scientific team and established an efficient new drug innovation system to develop globally innovative first-in-class and best-in-class drugs with independent intellectual property rights. For more information, please visit www.regor.com.